How the heart sugar transporter GLUT1 may cause diabetes-related heart damage
Role of GLUT1 in diabetic cardiomyopathy
This work looks at whether blocking a heart sugar transporter called GLUT1 can prevent or reduce heart damage in adults with diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11325461 on NIH RePORTER |
What this research studies
From my point of view as a patient, researchers are studying human heart tissue and using mouse hearts and isolated heart cells in the lab to see how excess sugar entering heart cells drives harmful changes. They focus on a chain of signals (GLUT1 → FOXO1 → KLF5) that appears to cause oxidative stress and fat-related damage in diabetic hearts. The team will map the signaling and metabolic pathways that link GLUT1 to heart injury and test whether inhibiting GLUT1 can protect the diabetic heart, especially in Type 2 diabetes. The work combines analysis of human samples with preclinical experiments to guide possible future therapies.
Who could benefit from this research
Good fit: Adults with diabetes, especially Type 2 diabetes, who are at risk for or have early signs of diabetic cardiomyopathy would be the most relevant candidates.
Not a fit: People whose heart problems are due to blocked coronary arteries, high blood pressure, valve disease, or who do not have diabetes are unlikely to benefit from GLUT1-targeted approaches.
Why it matters
Potential benefit: If successful, this research could point to new ways to prevent or slow heart failure caused by diabetes by targeting the GLUT1 pathway.
How similar studies have performed: Laboratory studies have linked glucose transport and the FOXO1–KLF5 pathway to heart injury, but directly targeting GLUT1 for diabetic cardiomyopathy is a relatively new and mostly preclinical approach with limited clinical evidence to date.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Drosatos, Konstantinos — University of Cincinnati
- Study coordinator: Drosatos, Konstantinos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.